drug
(empagliflozin + linagliptin + metformin hydrochloride) ER
Marketedupdated 5mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4indications
investigational
Type 2 Diabetes
all catalysts(7)
approval · 7
Jan 27, 2020
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Oct 30, 2020
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Jun 11, 2021
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Jun 11, 2021
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Oct 13, 2022
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Oct 30, 2023
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Oct 24, 2025
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 15, 2027
193 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (103)
- Dec 8, 2037patentUS 12364700*PED
- Dec 8, 2037patentUS 12364700*PED
- Dec 8, 2037patentUS 12364700*PED
- Dec 8, 2037patentUS 12364700*PED
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Dec 11, 2034patentUS 9949998*PED
- Dec 11, 2034patentUS 9949998*PED
- Dec 11, 2034patentUS 9949998*PED
- Dec 11, 2034patentUS 9949998*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Jun 11, 2034method-of-use (U-2731)US 9949998
- Jun 11, 2034method-of-use (U-2731)US 9949998
- Jun 11, 2034method-of-use (U-2731)US 9949998
- Jun 11, 2034method-of-use (U-2731)US 9949998
- Apr 3, 2034method-of-use (U-2731)US 10258637
- Apr 3, 2034method-of-use (U-2731)US 10258637
- Apr 3, 2034method-of-use (U-2731)US 10258637
- Apr 3, 2034method-of-use (U-2731)US 10258637
- Apr 3, 2034method-of-use (U-3192)US 11090323
- Apr 3, 2034method-of-use (U-3192)US 11090323
- Apr 3, 2034method-of-use (U-3192)US 11090323
- Apr 3, 2034method-of-use (U-3192)US 11090323
- Apr 3, 2034method-of-use (U-3777)US 11833166
- Apr 3, 2034method-of-use (U-3777)US 11833166
- Apr 3, 2034method-of-use (U-3777)US 11833166
- Apr 3, 2034method-of-use (U-3777)US 11833166
- Mar 7, 2032formulationUS 10596120
- Mar 7, 2032formulationUS 10596120
- Mar 7, 2032formulationUS 10596120
- Mar 7, 2032formulationUS 10596120
- Mar 7, 2032formulationUS 11564886
- Mar 7, 2032formulationUS 11564886
- Mar 7, 2032formulationUS 11564886
- Aug 11, 2030patentUS 12115179*PED3.9y
- Aug 11, 2030patentUS 12115179*PED3.9y
- Aug 11, 2030patentUS 12115179*PED3.9y
- Aug 11, 2030patentUS 12115179*PED3.9y
- Jun 15, 2030formulationUS 104061723.7y
- Jun 15, 2030formulationUS 104061723.7y
- Jun 15, 2030formulationUS 104061723.7y
- Jun 15, 2030formulationUS 104061723.7y
- May 21, 2030formulationUS 91557053.6y
- May 21, 2030formulationUS 91557053.6y
- May 21, 2030formulationUS 91557053.6y
- May 21, 2030formulationUS 91557053.6y
- Apr 14, 2030patentUS 8551957*PED3.5y
- Apr 14, 2030patentUS 8551957*PED3.5y
- Apr 14, 2030patentUS 8551957*PED3.5y
- Apr 14, 2030patentUS 8551957*PED3.5y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Oct 14, 2029formulationUS 85519573.0y
- Oct 14, 2029formulationUS 85519573.0y
- Oct 14, 2029formulationUS 85519573.0y
- Oct 14, 2029formulationUS 85519573.0y
- Apr 2, 2029formulationUS 100223792.5y
- Apr 2, 2029formulationUS 100223792.5y
- Apr 2, 2029formulationUS 100223792.5y
- Apr 2, 2029formulationUS 100223792.5y
- Apr 2, 2029formulationUS 94150162.5y
- Apr 2, 2029formulationUS 94150162.5y
- Apr 2, 2029formulationUS 94150162.5y
- Apr 2, 2029formulationUS 94150162.5y
- Feb 1, 2029patentUS 7579449*PED2.3y
- Feb 1, 2029patentUS 7579449*PED2.3y
- Feb 1, 2029patentUS 7579449*PED2.3y
- Feb 1, 2029patentUS 7579449*PED2.3y
- Aug 1, 2028compositionUS 75794491.8y
- Aug 1, 2028compositionUS 75794491.8y
- Aug 1, 2028compositionUS 75794491.8y
- Aug 1, 2028compositionUS 75794491.8y
- Oct 15, 2027patentUS 7713938*PED1.0y
- Oct 15, 2027patentUS 7713938*PED1.0y
- Oct 15, 2027patentUS 7713938*PED1.0y
- Oct 15, 2027patentUS 7713938*PED1.0y
- Apr 15, 2027compositionUS 7713938193d
- Apr 15, 2027compositionUS 7713938193d
- Apr 15, 2027compositionUS 7713938193d
- Apr 15, 2027compositionUS 7713938193d
- May 26, 2026patentUS 8883805*PED
- May 26, 2026patentUS 8883805*PED
- May 26, 2026patentUS 8883805*PED
- May 26, 2026patentUS 8883805*PED
- Nov 26, 2025formulationUS 8883805
- Nov 26, 2025formulationUS 8883805
- Nov 26, 2025formulationUS 8883805
- Nov 26, 2025formulationUS 8883805
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that